BFEC
LGND icon

Benjamin F. Edwards & Company’s Ligand Pharmaceuticals LGND Stock Holding History

Benjamin F. Edwards & Company’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$67K Buy
+790
New +$62.9K ﹤0.01% 1252
2020
Q2 		– Sell
-212
Closed -$10K – 1742
2020
Q1 		$10K Sell
212
-413
-66% -$23.4K ﹤0.01% 1251
2019
Q4 		$41K Sell
625
-32
-5% -$2.14K ﹤0.01% 1019
2019
Q3 		$41K Buy
657
+622
+1,777% +$39.1K ﹤0.01% 990
2019
Q2 		$3K Hold
35
– – ﹤0.01% 1742
2019
Q1 		$3K Buy
+35
New +$2.65K ﹤0.01% 1567

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Benjamin F. Edwards & Company's LGND Position: Q2 2024 in Review

Benjamin F. Edwards & Company opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2024: 790 shares worth $67K. The stake represents ﹤0.01% of the portfolio and ranks #1252 among its holdings. This is a return to the name: Benjamin F. Edwards & Company previously reported a position in LGND as recently as Q1 2020.

Benjamin F. Edwards & Company first reported a position in LGND in Q1 2019 and has held it in 6 quarters since. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Benjamin F. Edwards & Company held 790 shares of Ligand Pharmaceuticals worth $67K as of Q2 2024.
  • Ligand Pharmaceuticals was a new Benjamin F. Edwards & Company position in Q2 2024.
  • Ligand Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1252 holding.
  • Benjamin F. Edwards & Company first reported a position in Ligand Pharmaceuticals in Q1 2019 and has held it in 6 quarters since.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.